Scienture Holdings shares are trading higher after the company announced that Arbli Oral Suspension, 10 mg/mL has been added to the formulary of three leading U.S. pediatric academic medical centers and hospitals specializing in the treatment of children with complex and chronic medical conditions.

Scienture Holdings Issues Shareholder Letter Highlighting Financial and Commercial Progress

Scienture Holdings, Inc. released a letter to shareholders detailing a 256% sequential revenue growth for the first nine months of 2026 and progress toward 2027 profitability.

8-K filing — Scienture Holdings, Inc. (SCNX)

Filed: 2026-10-19 AccNo: 0001493152-26-047579 Size: 269 KB Item 2.02: Results of Operations and Financial Condition Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Item 9.01: Financial Statements and Exhibits

Scienture Holding shares are trading lower despite reporting preliminary Q3 revenue of $1.22 million, up 256% sequentially.

SCIENTURE HOLDINGS Reports Preliminary Q3 Revenue Of ~$1.22M

SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX) ("Scienture"), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers